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Abstract
Background: Nausea/vomiting (N/V) not related to anti-cancer treatment is common in patients with advanced
cancer. The standard approach to management is to define a dominant cause, and treat with an antiemetic
selected through pathophysiologic knowledge of emetic pathways. High rates of N/V control have been reported
using both etiology-based guideline-driven antiemetic regimens and an empiric approach using single agents in
uncontrolled studies. These different approaches had never been formally compared.
Methods: This randomized, prospective, open label, dose-escalating study used readily available antiemetics in
accordance with etiology-based guidelines or single agent therapy with haloperidol. Participants had a baseline
average nausea score of ≥3/10. Response was defined as a ≥ 2/10 point reduction on a numerical rating scale of
average nausea score with a final score < 3/10 at 72 h.
Results: Nausea scores and distress from nausea improved over time in the majority of the 185 patients
randomized. For those who completed each treatment day, a greater response rate was seen in the guideline arm
than the single agent arm at 24 h (49% vs 32%; p = 0.02), but not at 48 or 72 h. Response rates at 72 h in the
intention to treat analysis were 49 and 53% respectively, with no significant difference between arms (0·04; 95% CI:
-0·11, 0·19; p = 0·59). Over 80% of all participants reported an improved global impression of change. There were
few adverse events worse than baseline in either arm.
Conclusion: An etiology-based, guideline-directed approach to antiemetic therapy may offer more rapid benefit,
but is no better than single agent treatment with haloperidol at 72 h.
Clinical trial registration: Australian New Zealand Clinical Trials Registry: ANZCTRN12610000481077.
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Background
Nausea and vomiting (N/V) in patients with advanced
cancer is common, chronic and distressing with preva-
lence rates of up to 70% [1, 2]. In one study, 25% of
people admitted to a palliative care unit had nausea rat-
ings of > 50 on a 0–100 visual analogue scale [3]. The
negative influence on activities of daily living is signifi-
cant [4, 5]. N/V is often associated with other symptoms
such as pain and reflux within specific clusters [6].
There are multiple potential causes including organ
failure, central nervous system disease, drug therapy and
gastrointestinal obstruction/pathology, often with several
contributory factors in any one patient [7]. Management
involves treatment of the underlying cause(s), supportive
care measures (eg removal of bad odors, control of anx-
iety) and the delivery of antiemetics.
Current teaching when treating nausea is to define the
predominant cause and combine knowledge of the patho-
physiology of the vomiting process with the neuropharma-
cology of emetic pathways to determine which receptors
and neurotransmitters are best to target therapeutically.
The antiemetic medications known to be most active at
those receptors can then be prescribed [8]. A specific
cause is said to be identifiable in up to 90% of patients [1].
Several audits and uncontrolled studies have tested this
etiology-based approach and have demonstrated high
rates of nausea control [9–12]. Others have used single
antiemetic agents for all patients, irrespective of the cause
and have demonstrated similarly high rates of control [1].
The two different approaches have not previously been
tested against each other. In this study, the effectiveness
of a guideline-directed etiology-based approach to anti-
emetic management was compared to single agent (em-
pirical) management. The former was undertaken using
a clinical practice guideline, previously developed
according to best evidence of effect at the time [9].
Haloperidol was selected for the single agent arm, as it
is recommended as standard therapy for nausea in pal-
liative care practice [7, 8].
Methods
Study design
This open label, randomized controlled parallel arm trial
was undertaken by the Palliative Care Clinical Studies
Collaborative (PaCCSC) in 11 sites across Australia. The
study was approved by Human Research Ethics Commit-
tees covering all sites (Alfred Hospital (Victoria lead),
Hunter New England (NSW lead), Mater Health Ser-
vices, Southern Adelaide, St. Vincent’s Health & Aged
Care and Queensland University of Technology).
Patients
Participants > 18 years, had a diagnosis of cancer and
nausea with an average score of ≥3 on an 11 point (0–
10) NRS. They were not currently receiving antiemetics
or had received inappropriate antiemetics (as defined by
the antiemetic guidelines).
Patients were excluded if they: had a short term iatro-
genic or reversible cause of nausea for which there was
high level evidence that a specific antiemetic or inter-
vention was indicated (e.g., raised intracranial pressure
or acute chemo-radiotherapy induced nausea), were
likely to undergo any procedure with the potential to
affect nausea in the two days prior, or during the study
period, had a definite contraindication to any of the
study medications, a change in glucocorticoid dose
within 48 h, or poor performance status (that would
have rendered the participant unable to complete study
requirements).
Interventions
Investigators received formal training regarding the dif-
ferent mechanisms of nausea and vomiting and how to
determine a primary cause. All potential causes were re-
corded and a dominant mechanism defined if possible.
Randomization schedules were computer-generated
for each site at an independent central registry. Sched-
ules for each site were allocated in a 1:1 ratio in ran-
domly allocated blocks of two or four. Schedules held by
the central registry were sent to each site in opaque
sealed envelopes numbered in sequence. On notification
of an eligible patient, the research coordinator at each
site opened the next numbered envelope, allocated the
patient to the guideline treatment or single therapy arm,
and notified research staff and treating clinicians of the
treatment group allocation. It was not possible to blind
treatment in view of the number of medications utilized
and the complexities of dose escalation.
Those allocated to the guideline treatment group re-
ceived antiemetic therapy based on the etiology-based
clinical practice guidelines (CPGs) developed from a sys-
tematic review of the efficacy of antiemetics in patients
with far-advanced cancer by Glare et al. [9]. The CPGs
were updated and modified by consensus using an ex-
pert panel following review of the recent literature. The
CPGs (Table 1) specify common mechanisms of nausea
(categories A-G) and for each mechanism, recommend
first line treatment, with subsequent lines of treatment
in a step-wise fashion, every 24 h, if nausea remained
uncontrolled. For multiple contributing factors, investi-
gators were instructed to treat according to the primary
or dominant contributing factor. The CPGs were
adapted to include recommended treatment options for
patients in whom a primary cause could not be deter-
mined (category H). The oral route was preferred for all
study medicines, but parenteral routes were allowed for
those unable to take oral medications.
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Participants allocated to the single agent group
received haloperidol (1.0 mg/24 h) orally or parenterally
(subcutaneous or intravenous). In patients with uncon-
trolled nausea, the dose was increased in a step-wise
fashion every 24 h to 2 mg and then to a maximum of
3 mg/24 h.
Metoclopramide 10 mg was charted as a rescue anti-
emetic to be given 4 hourly as required (prn), except in
those arms where metoclopramide was already being
delivered 4 hourly in which case haloperidol (0·5 mg prn
to 6 hourly) was used for breakthrough.
Patients who did not meet the response definition at
24 h proceeded to second and third line antiemetic ther-
apy according to the CPGs. Patients who met the re-
sponse definition at 24 h remained on the same
antiemetic regimen. At 72 h, participants whose nausea
had been controlled remained on the effective medica-
tion and dose level. Patients with refractory nausea (final
score ≥ 3/10) were managed at the discretion of the
treating clinician.
Outcome measures
Assessments of nausea severity and distress were under-
taken daily. Other measures were: performance status
[13], symptom burden [14], quality of life [15], co-
morbidities [16], and toxicity [17, 18].
A response was defined as at least a 2-point reduction
in average nausea score and a score < 3 for average
nausea over the preceding 24 h, measured at 72 h on an
11-point numerical rating scale (NRS).
The primary outcome measure was a response at 72 h
(end day 3). Secondary outcomes measured at 72 h in-
cluded: average, best and worst nausea scores, nausea
distress, the number of patients treated at each dose
level, rescue doses delivered, episodes of vomiting, global
impression of change and adverse events.
Statistical analysis
The primary hypothesis of no difference in response
rates at 72 h was tested using chi-square tests of differ-
ences between treatments. Assuming a response rate of
75% in the guideline arm and 50% in the single agent
arm, a minimum of 150 participants (75 per group) who
completed 72 h of treatment was deemed adequate to
detect an absolute and clinically relevant difference in
response rates of 25% between single agent and guide-
line therapy, with 90% power, assuming a two-tailed
Type 1 error of 5% and a simple random sampling
scheme.
In the primary intention-to-treat (ITT) analysis, ran-
domized patients who withdrew for any reason were
classified as ‘non-responders’. A secondary analysis was
conducted as a ‘per protocol’ analysis of patients who
completed 72 h of trial medication. Descriptive statistics
were generated from the patient’s demographic and clin-
ical characteristics. Chi-square analysis was used to
Table 1 Clinical practice guidelines for the management of nausea
Dominant cause Treatment Step 1 Treatment Step 2 Treatment Step 3
A: Central/chemoreceptor
trigger zone (CTZ) stimulation
Prochlorperazine 5 mg tds po or 25 mg
PR then 5 mg tds po or 12.5 mg bd
IM/iv
Haloperidol 1.5 mg/24 h po
or sc
Haloperidol 3 mg/24 h po or sc
B: Central nervous system
(CNS) disease
Dexamethasone 8 mg/24 h po/sc/iv Dexamethasone 12 mg/24 h po/sc/
iv
Dexamethasone 16 mg/24 h po/sc/iv
C: Vestibular involvement Prochlorperazine 5 mg tds po or 25
mg PR then 5 mg tds po or 12.5 mg
bd IM/iv
Prochlorperazine 10 mg tds
po or 25 mg PR then 10 mg
tds po or 12.5 mg tds IM/iv
Promethazine 25 mg tds po or
12.5 mg sc then 10 mg tds po
D: Gastric stasis Metoclopramide 10 mg qid po/sc/iv Metoclopramide 10 mg
Q4h po/sc/iv
Metoclopramide 10 mg Q4h po/sc/iv
Dexamethasone 8 mg/24 h po/sc/iv
E: Ileus Metoclopramide 10 mg qid po/sc/iv Metoclopramide 10 mg
Q4h po/sc/iv
Metoclopramide 10 mg Q4h po/sc/iv
Dexamethasone 8 mg/24 h po/sc/iv
F: Mechanical obstruction Haloperidol 1.5 mg/24 h po/sc
Dexamethasone 8 mg/24 h po/sc/v
Haloperidol 3 mg/24 h
po/sc
Dexamethasone 8 mg/24 h po/sc/iv
Haloperidol 3 mg/24 h po/sc
Dexamethasone 8 mg/24 h po/sc/iv
Hyoscine butylbromide 80 mg/24 h sc
or Ranitidine 200 mg/24 h sc









Metoclopramide 10 mg qid po/sc/iv Metoclopramide 10 mg
qid po/sc/iv
Haloperidol 1.5 mg/24 h
po/sc
Metoclopramide 10 mg Q4h po/sc/iv
Haloperidol 3 mg/24 h po/sc
Po by mouth, PR per rectum, sc subcutaneous, iv intravenous, IM intramuscular, bd twice daily, tds three times daily, qid four times daily, Q4h four hourly, PPI
proton pump inhibitor, Min minimum, Max maximum
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detect any differences between treatment groups at
baseline.
In secondary cross-sectional analyses, each endpoint
was considered separately. Regression modeling of nausea
scores over time and the impact of the intervention on
these trends were conducted under the assumption of
‘missing at random’, implementing a linear mixed models
approach to adjust for potential confounding and ensure
that individuals with missing data over time may be in-
cluded as far as their data permit. Results are expressed as
prevalence rates, median and range, mean and standard
deviation, depending on the data type and analysis.
Results
Of the 211 potential participants assessed for eligibility,
185 patients were randomized between October 2010
and April 2014. Four patients (all randomized to single
agent) were subsequently deleted from the analysis: one
patient was randomized twice and three patients were
subsequently proven to be ineligible. The intention-to-
treat (ITT) sample comprised 86 patients assigned to
single agent treatment and 95 to the guideline group.
Patient flow is presented in Fig. 1. At 72 h, 74 patients
had completed single agent treatment and 72 guideline
treatment, giving an attrition rate of 21% (35/181).
Randomization achieved two groups that were similar
with respect to baseline characteristics (Table 2). The
average and worst nausea scores at baseline in both arms
was around 5/10 and 7/10. Nausea distress was reflected
by a mean nausea distress score of around 5/10 in both
arms. The majority of participants (85%) had received
anti-emetics in the week prior to study. Nausea was con-
sidered to be multi-factorial in origin in 79% of partici-
pants randomized to single agent and 71% to guideline
therapy. A dominant cause for N/V (most commonly
central/CTZ stimulation and gastric stasis) could be de-
termined in 47% of single agent and 60% of guideline
participants.
Fig. 1 Participant flow
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Table 2 Patients’ demographic and medical characteristics by treatment arm
Single agent (n = 86) Guideline Therapy (n = 95)
Characteristic No. % Mean SD No. % Mean SD
Age (years) 69.3 14.3 68.1 13.0
Male gender 23 27.4 34 35.8
Place of care
Inpatient palliative care 29 34.5 36 37.9
Hospital general ward 28 33.3 37 38.9
Private home 27 32.1 22 23.2
Primary Cancer Diagnosis
Breast 8 9.3 15 15.8
Lung 9 10.5 12 12.6
Colorectal 12 14.0 9 9.5
Gynaecologic 14 16.3 12 12.6
Gastrointestinal 4 4.7 6 6.3
Pancreas 6 7.0 5 5.3
Prostate 5 5.8 11 11.6
Other 23 26.7 19 20.0
Unknown 5 5.8 6 6.3
Performance statusa (0–100)
Median (Interquartile range) 60 (50–70) 60 (50–70)
Quality of lifeb (1–7) 3.0 1.3 3.0 1.3
Symptom burdenc (0–90) 37.3 16.1 39.0 13.7
Charlson Comorbidity Index 6.1 2.4 6.6 2.1
Vomited in last 24 h 28 30 31.6
(Yes) 32.6
Number of vomiting episodes 0 0 (0–10)
Median (range) (0–5)
Duration of current nausea 13 20 21.1
< 1 week 18 26 27.4
1 up to 2 weeks 18 15.5 21 22.1
2 up to 4 weeks 15 21.4 13 13.7
1 up to 2 months 20 21.4 15 15.8
≥ 2 months 17.9
23.8
Nausea score (0–10)
Worst 7.6 1.8 7.4 1.9
Best 2.1 1.8 1.8 2.0
Average 5.2 1.4 5.0 1.5
Distress 4.9 3.0 5.2 3.2
Nausea Interferenced (0–100) 43.6 27.3 43.8 26.0
Nausea - multi-factorial 68 79.1 67 70.5
Dominant cause
Undetermined 46 53.5 38 40.0
Central/CTZe stimulation 16 18.6 27 28.4
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In the primary (ITT) analysis, the response to treatment
at 72 h was 53% (46/86) in the single agent arm and 49%
(47/95) in the guideline therapy arm with no difference
between groups (0.04; 95% CI: -0.11, 0.19; p = 0.59). In the
per protocol analysis, there was no difference in response
rates; (62% (46/74) single agent and 65% (47/72) guideline
therapy) (− 0.03; 95% CI: -0.19, 0.13; p = 0.70). Similarly,
there was no difference in response rates between arms
(ITT) using ‘worst’ nausea. For those who completed each
treatment day, greater response rates were seen in the
guideline arm than the single agent arm at 24 h (49% vs
32%, p = 0.02), but not at 48 (69% vs 59%, p = 0.17) and
72 h (65% vs (62%, p = 0.70).
Multivariate analyses of nausea scores as continuous
variables were conducted to investigate the effects of
time, group and time*group interaction. From the trajec-
tory of mean nausea scores (Fig. 2), average, best and
worst nausea scores all improved over time (p < .001).
Only mean scores of average nausea differed significantly
between treatment arms.
After treatment completion (72 h), patients in both
arms were less distressed by nausea. Mean distress
Table 2 Patients’ demographic and medical characteristics by treatment arm (Continued)
Single agent (n = 86) Guideline Therapy (n = 95)
Characteristic No. % Mean SD No. % Mean SD
Gastric stasis 8 9.3 12 12.6
Other 16 18.6 18 18.9
Adverse eventf
Fatigue 63 73.3 74 77.9
Anticholinergic effects 48 55.8 63 66.3
Gastrointestinal upset 51 59.3 57 60.0
Anorexia 50 58.1 57 60.0
Drowsiness 42 48.8 53 55.8
Dizziness 17 19.8 17 17.9
Hyper/hypotension 12 14.0 14 14.7
Restlessness 4 4.7 5 5.3
Extrapyramidal reactions 1 1.0 1 1.0
Incoordination 0 0.0 4 4.2
aAustralian-modified Karnofsky performance status scale
bEORTC-QLQ-C15-PAL
cEdmonton Symptom Assessment Scale
dNausea Interference Scale
eChemo Receptor Trigger Zone
fAny grade
Fig. 2 Mean score - worst, average and best nausea by treatment over time
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scores for single agent were 2.5 (95% CI, 1.9–3.2) com-
pared to baseline 4.9 (95% CI: 4.2, 5.5) and 2.3 (95% CI:
1.6, 3.0) compared baseline 5.2 (95% CI: 4.6, 5.8) for
guideline therapy.
The percentage of participants treated at each dose
level over time is shown in Table 3. The majority of par-
ticipants completed the study on steps 1 or 2. Approxi-
mately one-third of all participants were given rescue
antiemetics each day with a greater use of rescue medi-
cations in the single agent arm at 48 h (43% vs 22%, p =
0.003) but not at 24 or 72 h (42% vs 33%, p = 0.25 and
35% vs 27%, p = 0.31).
The percentage of participants reporting ≥1 episode of
vomiting/day decreased from around 33% at baseline to
17% at 72 h in both treatment arms. At 72 h, compared
to 24 h, the proportion of patients reporting improve-
ment in global impression of change (GIC) increased
from 64 to 86% (single agent) and from 70 to 82%
(guideline therapy). In a longitudinal analysis, GIC im-
proved over time (p < ·001) with no difference between
treatment arms.
Adverse events were common at baseline with over
50% of all participants reporting fatigue, gastrointestinal
upset, anorexia or anticholinergic effects (dry eyes, dry
mouth, tremor) (Table 2). Treatment related adverse
events are shown in Table 4.
Discussion
Contrary to current teaching [8], we have not shown
aetiology-based guideline directed therapy aimed at the
presumptive cause of nausea to be superior to the regu-
lar administration of a single agent (haloperidol) at 72 h.
Moreover, it has shown that N/V not acutely related to
anti-cancer therapy can be controlled relatively rapidly
in the majority of patients with cancer, at least in the
short term, using currently available inexpensive medica-
tions regularly at recommended dosing levels.
The guidelines determined a specific treatment path-
way for these patients based on best available evidence
of antiemetic efficacy, using freely available antiemetics
approved for this indication. The evidence to guide
antiemetic use in this scenario is poor, with no high
quality randomized controlled trials of individual drugs
identified in the most recent review that recommends
metoclopramide as the single drug of choice, with halo-
peridol listed as an appropriate second-line agents [19].
Haloperidol was selected as the single agent for this
study as it is a relatively broad spectrum antiemetic used
commonly in supportive and palliative care [7] and be-
cause metoclopramide was often the drug of choice
within the guideline. Doses chosen for initiating and ti-
trating therapy were determined by consensus as robust
dose-ranging studies were not available.
Compliance with the allocated medication regimen
ranged from 83 to 93% with a tendency towards greater
compliance in the guideline arm. This was a “real world”
study meant to mirror everyday practice rather than a
rigid dose escalation trial. Similarly, the use of both oral
and parenteral formulations reflects patient need in ad-
vanced disease.
The guideline approach resulted in superior nausea
control at 24 h and in the use of rescue antiemetics at
48 h, but the benefit was not sustained at 72 h. This is
Table 3 Proportion of patients in each treatment arm by current dose step at each time
Time Dose step Single agent (haloperidol) Guideline therapy Total Chi-square,
p-valueN n (%) N n (%) N n (%)
24 h Step 1 82 82 (100) 92 92(100) 174 174 (100)
48 ha Step 1 28 (37.3) 45 (54.2) 74 (46.5)
Step 2 75 47 (62.7) 83 38 (45.8) 158 85 (53.5) Χ2 = 4.5,
p = 0.03
72 h Step 1 75 23 (30.7) 74 36 (48.4) 149 59 (39.6)
Step 2 30 (40.0) 25 (33.8) 55 (36.9) Χ2 = 5.6,
Step 3 22 (29.3) 13 (17.6) 35 (23.5) p = 0.06
aOne patient on Step 1 escalated to Step 3 due to rescue medications given
Table 4 Number of Adverse Events graded worse at 72 h than
at baseline






Anticholinergic effects 12 8







Extrapyramidal reactions 0 1
aAny grade
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important when aiming for a rapid improvement in
symptom control and quality of life in patients with
advanced disease.
The medications were well tolerated. There was a
single report of an extra-pyramidal reaction. This low
rate is consistent with reports in other palliative care
populations [20].
It is often not possible nor appropriate to undertake
complex investigations to look for an exact cause of nau-
sea in patients with advanced disease [8, 21]. Those with
nausea of known cause for which there is a clear
evidence-based treatment (such as 5HT3 antagonists for
chemo/radiotherapy induced vomiting), were excluded.
A primary cause could only be defined in 54% of all par-
ticipants which is lower than that reported in uncon-
trolled studies assessing guideline therapy and limits the
usefulness of an etiology-based approach [1, 9]. The ma-
jority of participants in whom a cause could be deter-
mined were thought to have nausea related to a central
cause, often medication related.
This study focused on nausea, whereas most other
studies in cancer patients have used complete control of
emesis as the primary end-point in the setting of
chemotherapy-induced nausea and vomiting [22]. The
need to control delayed nausea following chemotherapy
has been recognized [23] and of “freedom from clinically
significant nausea” (a nausea score of < 3 on an 11-point
scale), has been used as an end-point [24]. The response
definition used in this study was extrapolated from the
pain literature in which a 2-point reduction on an 11-
point NRS is considered clinically significant [25]. A
final score within the “severe nausea” category is unlikely
to reflect a clinically meaningful response hence our re-
quirement for a final score of ≤3/10.
Guideline therapy is more difficult to institute. The
sample size was calculated on the premise that a 25%
improvement over single agent therapy would be clinic-
ally relevant and necessary in order to support the
practice.
It was not possible to blind this study in view of the
multiple medications involved and the complexity of the
dose prescription and escalation process. Similarly, this
was a short 3-day study as there is an urgency to relieve
symptoms in this population group. Whether the results
could be duplicated over a longer time period is un-
known. There was some overlap in the guidelines with
several arms targeting gastrointestinal causes of N/V.
Other guidelines have relied more on investigations to
determine a likely cause of nausea before deciding on
appropriate treatment [26]. The primary aim of this
study was to test an etiology-based guideline approach
to antiemetic control. This resulted in the potential limi-
tation of testing “like with like” in that haloperidol was
also a part of the CPG. This could have contributed to
the null result. Similarly, several of the antiemetics used
are dopamine receptor antagonists with a similar mech-
anism of action as haloperidol.
Conclusion
We have been unable to show that a mechanistic
approach to N/V is superior to an empirical approach
using a single agent given at adequate dose regularly in a
dose-escalated manner. Moreover, N/V is often multifac-
torial or the primary cause cannot be determined. The
response rate in this study was high in both arms sug-
gesting that the use of low cost anti-emetics currently
available can achieve good symptom control in many
cases. Other more expensive antiemetics with little or no
evidence of benefit in this setting should only be used in
those with refractory nausea or in the context of a clin-
ical trial.
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